Mantle Peter
Faculty of Natural Sciences, Imperial College London, South Kensington, London SW7 2AZ, UK.
Antibiotics (Basel). 2019 Feb 4;8(1):14. doi: 10.3390/antibiotics8010014.
The recent demonstration for the first time of urinary monic acid A as a clinical urinary biomarker of exposure to intra-nasal mupirocin during medication for methicillin-resistant (MRSA) offers a way of verifying adherence to the regimen. However, absence of the biomarker in some patients needs explanation, to ensure that efficient decolonisation has not been compromised by confounding circumstances, and that additional resistance to mupirocin has not unwittingly been encouraged.
最近首次证明,在耐甲氧西林金黄色葡萄球菌(MRSA)治疗期间,尿液中的莫能菌素A可作为鼻腔使用莫匹罗星暴露情况的临床尿液生物标志物,这为验证是否遵守治疗方案提供了一种方法。然而,部分患者未检测到该生物标志物的情况需要作出解释,以确保有效的去定植未因混杂因素而受到影响,且未无意中助长对莫匹罗星的额外耐药性。